Development of a sandwich ELISA to detect *Leishmania* 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients

Wen-Wei Zhang¹, Ayan Kumar Ghosh², Raodoh Mohamath³, Jacqueline Whittle³, Alessandro Picone³, Patrick Lypaczewski¹, Momar Ndao⁴, Randall F Howard³, Pradeep Das², Steven G Reed³ and Greg Matlashewski¹*

**Abstract**

**Background:** Visceral leishmaniasis (VL), caused by *Leishmania donovani* complex parasites, is a neglected parasitic disease that is generally fatal if untreated. Despite decades of research to develop a sensitive VL diagnostic test, definitive diagnosis of VL still mainly relies on the visualization of the parasite in aspirates from the spleen, liver or bone marrow, an invasive and dangerous process with variable sensitivity. A sensitive assay that can detect *Leishmania* antigen from blood samples will help confirm cause, cure or recurrence of VL.

**Methods:** In this study, rabbit polyclonal antibodies were raised against eight recombinant *Leishmania* proteins that are highly abundant in *Leishmania*. The antibodies were purified and labeled with biotin for developing a prototype sandwich enzyme-linked immunosorbent assay (ELISA).

**Results:** The ELISA for the *Leishmania* 40S ribosomal protein S12 detected target antigen with the highest sensitivity and specificity and could detect 1 pg of purified protein or as few as 60 *L. donovani* parasites. The 40S ribosomal protein S12 sandwich ELISA could detect the target antigen from Peripheral Blood Mononuclear Cell (PBMC) samples in 68% of VL patients and post-kala-azar dermal leishmaniasis (PKDL) patients, providing an estimation of parasitemia ranging from 15 to 80 amastigotes per ml of blood.

**Conclusion:** These results indicate that the 40S ribosomal protein S12 sandwich ELISA warrants further tests with more clinical samples of VL patients and other parasitic diseases. It is hopeful that this ELISA could become a useful tool for confirming VL diagnosis, monitoring treatment progress, disease recurrence and possibly detecting asymptomatic *Leishmania* infections with a high parasite load.

**Keywords:** Visceral Leishmaniasis, Diagnosis, ELISA, PBMC, 40S ribosomal protein S12

**Background**

*Leishmaniasis* is caused by the protozoan *Leishmania* parasites, which are transmitted by the bite of infected sandflies. Depending on the infecting species, *Leishmania* infection can cause cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL) or visceral leishmaniasis (VL). VL, also known as kala-azar, is the most serious form of the disease and is frequently fatal if left untreated [1, 2]. VL is highly endemic in the Indian sub-continent, East Africa and parts of South America. An estimated 50,000 to 90,000 new cases of VL occur worldwide each year (http://www.who.int/news-room/fact-sheets/detail/leishmaniasis). Due to the AIDS epidemic, coinfection with human immunodeficiency virus (HIV) has increased VL cases in some parts of the world [3]. In addition, *Leishmania infantum* infection causes visceral disease in domestic dogs, which are the major vertebrate reservoirs for transmission to humans in Latin America and Southern Europe [4, 5].
VL is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. However, these clinical features are not specific and can be mistaken for other common illnesses associated with fever including malaria. Moreover, infection with *Leishmania* does not always lead to clinical illness, asymptomatic infections are common, and it is unknown whether these individuals represent a source of transmission [6, 7]. Although there are some drawbacks associated with the current treatments, VL is a life-threatening disease that is curable with proper treatment [7]. Therefore, rapid and accurate diagnosis of visceral *Leishmania* infection is important for patients to receive prompt treatment, determine cure or an indication of relapse, and thus prevent further transmission of this disease [7].

Currently, diagnosis of VL is made by combining clinical symptoms with parasitological or serological tests. Assays based on detection of parasite-specific antibodies (such as the rK39 test) have proven to be efficient for VL diagnosis. The rK39 immunochromatographic test (ICT) is easy to perform, rapid and inexpensive. However, because the rK39 ICT detects antibodies, it cannot distinguish relapse cases from past infection, or active disease from asymptomatic infection and cannot be used as a test of cure [8–10]. The rK39 ICT is less effective in VL patients co-infected with HIV and is more sensitive for VL diagnosis in Asia than in Africa [8–10], though the new rK28 ICT has improved the detecting sensitivity of VL cases in Africa [11].

Nucleic acid-based diagnostics such as polymerase chain reaction (PCR) are the most sensitive method to detect the presence of parasites in clinical samples, but they are expensive and restricted to referral hospitals and research centers, though this situation could be improved with development of loop-mediated isothermal amplification (LAMP) assays where there has been recent progress [12–17]. Definitive diagnosis of VL still requires microscopic identification of the parasite in internal organs such as in spleen, liver or bone marrow aspirates, an invasive and dangerous process with varied sensitivity (53–99%) [8–10]. Therefore, development of an assay that can sensitively detect *Leishmania* antigen from blood or urine samples would be helpful for rapid and definitive VL diagnosis, test of cure and relapse [18–24].

Based on the hypothesis that abundant *Leishmania* proteins could be easier to detect than low abundance proteins, we raised rabbit polyclonal antibodies against eight *Leishmania* proteins previously reported to be highly abundant in *Leishmania* [25–27]. With these rabbit antisera, we developed a direct enzyme-linked immunosorbent assay (ELISA), and a sandwich ELISA with purified antibodies labeled with biotin for detection of the *Leishmania* antigens. The sandwich ELISA against the *Leishmania* 40S ribosomal protein S12 provided the highest sensitivity and specificity. Importantly, the sandwich ELISA could detect *Leishmania* 40S ribosomal protein S12 antigen in PBMC lysates prepared from VL patients and post-kala-azar dermal leishmaniasis (PKDL) patients. These results suggest that the 40S ribosomal protein S12 sandwich ELISA could represent a useful test for confirming VL diagnosis and for monitoring treatment progress and relapse.

**Methods**

**Selection of abundant *Leishmania* proteins**

The ten soluble and abundant *Leishmania* proteins we selected (Table 1) were based on previous *Leishmania* proteomic analysis, these proteins were present as large and dense spots in two-dimension gel electrophoresis and were identified using mass spectrometry [25, 26]. The abundance of these selected proteins was also confirmed by our own more recent proteomic study on *L. donovani* [27]. Most of these abundant *Leishmania* proteins except aldolase (LmjF.36.1260) have low homology to human proteins.

**Construction of bacterial expression vectors**

For convenience of cloning, we have replaced the sequence (Nde I to Not I) containing the S. Tag and the multiple cloning sites in pET29 bacterial expression vector (Novagen) with following sequence containing a His-Tag sequence and new multiple cloning sites (Hind III, Kpn I, EcoR I, BamH I, Bgl II and Not I): CATATGGCACATCA CCACCACCATCAACAAGCTTGTTACCGAATTCCGAT

| Systematic Name | Simplified Name | Encoded Protein | Molecular weight (kDa) |
|-----------------|-----------------|-----------------|-----------------------|
| LmjF.05.0350    | 53S             | Trypanothione reductase | 53.1                  |
| LmjF.05.0450    | 54S             | Kinetochore related protein | 22.3                  |
| LmjF.05.0830    | 58S             | Methylthioadenosine phosphorylase | 33.4                  |
| LmjF.13.0570    | 13S             | 40S ribosomal protein S12 | 15.6                  |
| LmjF.24.1500    | 2415            | Translationally controlled tumor protein | 19.4                  |
| LmjF.32.0460    | 3246            | Prostaglandin F synthase | 31.8                  |
| LmjF.35.0820    | 3582            | Aspartate aminotransferase | 45.9                  |
| LmjF.24.2110    | 24,211          | 3-Hydroxy-3-methyl glutaryl-CoA synthase | 55.2                  |
| LmjF.36.1260    | 36,126          | Fructose-1,6-bisphosphate aldolase | 40.8                  |
| LmjF.36.6760    | 36,676          | ATP synthase delta (ICSP) subunit | 28.9                  |

*Because of low yield, these proteins were not sent for production of antisera
CCAGATCT GTAGCGGCCGC. We re-named the modified pET29 vector as pET29w. Accordingly, the primers with corresponding restriction enzyme site added at the 5′ end were designed and used to amplify the gene sequences of these abundant Leishmania proteins by PCR using L. donovani genomic DNA as the template. The Leishmania gene PCR products with expected sizes were digested with restriction enzymes and cloned into the corresponding sites of pET29w bacterial expression vector. A list of these primer pairs is shown in Table 2.

Expression and purification of recombinant Leishmania proteins in E. coli BL21 or Rosetta cells
We isolated the recombinant Leishmania proteins from bacteria by following the manufacturer's protocol (Novagen pET system manual). Some of these recombinant proteins formed Inclusion Bodies after Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction of the culture and were first urea-solubilized before using Ni-NTA Agarose resin (Qiagen) to purify. Depending on the protein, we obtained 2–10 mg of each recombinant protein from 1 L shake cultures for polyclonal antibody production.

Production of rabbit polyclonal antibodies
The rabbit polyclonal antibodies (antisera) against these abundant Leishmania proteins were produced by Syd Labs, Inc. (Natick, MA, USA). The detailed procedures can be found in the website of Syd Labs, Inc. (https://www.sydlabs.com). One or two rabbits were immunized for each Leishmania recombinant protein with Freund’s adjuvant (SIGMA, USA). About 0.5 ml of pre-immune rabbit serum and 40 to 80 ml of antiserum with ELISA titers > 1:20,000 were obtained within 4 months for each antigen. The antisera were kept at 4 °C for current use and in a – 20 °C freezer for longer storage.

Leishmania strains and macrophage infection
The L. donovani 1S/Cl2D and Leishmania major Friedlin V9 strains used in this study were routinely cultured at 27 °C in M199 medium (Cat # M0393, SIGMA) supplemented with 10% heat-inactivated fetal bovine serum, 40 mM HEPES (pH 7.4), 0.1 mM adenine, 1 mg l⁻¹ hemin, 1 mg l⁻¹ biotin, 1 mg l⁻¹ biotinophore, 50 U ml⁻¹ penicillin and 50 μg ml⁻¹ streptomycin. Cultures were passaged to fresh medium in a 20-fold dilution once a week. Infection of cultured macrophages was performed as described [28].

Western blot analysis of abundant Leishmania proteins
Whole cell lysates were prepared in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer from L. major promastigotes, L. donovani promastigotes, L. donovani axenic amastigotes, and human H1299 epithelial cells. After boiling in water for 3 min and centrifuging at 15,000 RPM (Revolutions per

---

**Table 2** A list of primers used to amplify genes encoding abundant Leishmania proteins

| Systematic Name | Primer pairs used for PCR | Gene size (bp) |
|-----------------|---------------------------|---------------|
| LmjF.05.0350    | 5’ cccaaagcttaccATGTCECCGGCGCTACGCCTCG 1476 |
| LmjF.05.0450    | 5’ cccaaagcttaccATGCTGAGGAAACCGTCCGTGTTG 591 |
| LmjF.05.0830    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 921 |
| LmjF.13.0570    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 513 |
| LmjF.24.1500    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 840 |
| LmjF.32.0460    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 1239 |
| LmjF.35.0820    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 1506 |
| LmjF.36.1260    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 1116 |
| LmjF.36.6760    | 5’ cccaaagcttaccATGGCAGCGAAGGCCGTTATAGA 777 |
minute) for 10 min, the cell lysate supernatants were separated in SDS-PAGE gel and subjected to Western blot analysis [29]. Rabbit antiserum was diluted 1:1000 for Western blot analysis to detect target proteins in *Leishmania* cell lysates (4 × 10^7 *Leishmania* cells per lane).

Isolation of peripheral blood mononuclear cells (PBMCs) from clinical samples
The diagnosis for most of the VL patients at the Rejandra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, Bihar was confirmed by spleen or bone marrow biopsies. PKDL cases at RMRIMS were confirmed by skin smear microscopy for LD bodies (Amastigotes). The healthy controls were all rK39-negative but biopsy-negative, 3 PKDL patients and 12 healthy controls were recruited. The 14 VL cases included 10 males with age range from 3 to 52 years old and 4 females with age range 18 to 35; the 5 likely VL cases which had typical VL symptoms and were rK39-positive but biopsy-negative, 3 PKDL patients and 12 healthy controls were utilized for preparation of PBMCs with Ficoll-density separation [30]. PBMC lysates were prepared by lysing cells in 1% NP-40 in PBS with proteinase inhibitors (cOmplete Cocktail Tablets, SIGMA) at the concentration of 1 × 10^7 cells/ml. After incubation on ice for 30 min with occasional mixing, the lysates were centrifuged at 4 °C at high speed (15,000 RPM) for 15 min, and the supernatant was kept and stored at -20 °C until use.

Direct ELISA
*L. donovani* promastigote lysate was prepared by lysing cells in 1% NP-40 in PBS (Phosphate-buffered saline) with proteinase inhibitors at the concentration of 4 × 10^8 cells/ml. After centrifugation at 4 °C at high speed for 15 min, the supernatant was stored at -20 °C until use.

The ELISA plate (Immulon cat#: 62402–972 from VWR) was coated with 50 μl (per well) cell lysate diluted in carbonate/bicarbonate buffer (1.89 g NaHCO₃ and 0.954 g Na₂CO₃ in 500 ml H₂O, pH 9.6) and incubated at 4 °C in a moist chamber overnight. The plate was washed 2 times with 200 μl wash buffer (0.05% Tween 20 in PBS) then blocked with 200 μl/well blocking buffer (5% nonfat dry milk in 0.1% PBS/T) for 1 h at 37 °C (covered with an adhesive plastic). The plate was washed 2 times with wash buffer, and 100 μl rabbit antiserum in 1:2000 dilution in blocking buffer was added to each well for 1.5 h at 37 °C or overnight at 4 °C. The plate was washed 3 times with wash buffer and 100 μl of horseradish peroxidase (HRP)-linked anti-rabbit antibody (ECL NA934V 1:5000 in blocking buffer) was added into each well for 1 h at 37 °C. The plate was washed 4 times with wash buffer followed by adding 50 μl/well of the HRP substrate TMB (eBioscience). After 10 min incubation at room temperature, the reactions were stopped with 25 μl of 1 N H₂SO₄. The color change in wells was read at 450 nm absorbance.

Purification and labelling of rabbit anti-*Leishmania* protein antibodies
To set up the sandwich ELISA, Immunoglobulin G (IgG) was first purified from the rabbit antiserum with the Melon Gel IgG Purification System (Cat # 45206, Thermo Fisher Scientific), which purifies antibodies from serum by removing non-relevant proteins. After dilution with the Melon gel purification buffer (1:10) and passing through the Melon gel purification column, 100 μl of serum generated 1000 μl of purified IgG. One-half of the purified IgGs were biotin labeled using the Thermo Scientific EZ-Link Sulfo-NHS-SS-Biotin (sulfosuccinimidyl-2-[biotinamido]ethyl-1,3-dithiopropionate, Cat # 21331). 7 μl Sulfo-NHS-SS-Biotin (6 mg/ml, freshly prepared) was added into 500 μl purified rabbit IgG and labeled at 4° C overnight. Free Sulfo-NHS-SS-Biotin was removed from the labeling reaction by dialysis in PBS.

Sandwich ELISA
A 96-well ELISA plate was coated with 100 μl/well of capture antibody in carbonate/bicarbonate coating buffer (i.e. 0.5 μl capture ab + 100 μl coating buffer; 1:200 dilution). The plate was sealed and incubated overnight at 4 °C in a moist chamber. Wells were aspirated and washed 5 times with 250 μl/well wash buffer (0.05% Tween 20 in PBS) allowing time for soaking (~ 1 min) during each wash step. Absorbent paper was used to remove any residual buffer. Wells were blocked with 200 μl/well of 2% bovine serum albumin (BSA) in PBS, incubated at 37 °C for 2 h, and aspirated and washed 2 times. A 2-fold serial dilution of the standards (*L. donovani* promastigote lysate alone or mixed with the healthy control PBMC lysate) was performed with assay buffer (1% BSA in wash buffer) with a final volume of 100 μl per well to generate the standard curve. PBMC lysates of clinical samples (100-250 μl) prepared as above were added into each well. The plate was covered, incubated overnight at 4 °C, aspirated free of buffer, and washed 5 times. Detection antibody (100 μl/well) diluted in assay buffer (i.e., 0.25 μl Detection ab-Biotin + 100 μl Assay buffer; 1:400 dilution) was added per well, and the plate was sealed and incubated at 37 °C for 2 h. Wells were aspirated and washed 5 times, and 100 μl/well of Avidin-HRP (eBioscience) diluted in assay buffer (1:250 dilution) was added and incubated at room temperature...
for 30 min to 1 h. Wells were aspirated and washed 10 to 14 times with the wells soaking for 2 min for each wash. Substrate solution (TMB; 100 μl/well) was added, and plates incubated at room temperature for 15 min. The reactions were stopped by adding 50 μl/well of Stop Solution (2 N H₂SO₄), and absorbance was read at 450 nm.

**Generation of monoclonal antibodies against peptides of *L. donovani* 40S ribosomal protein S12**

Monoclonal antibodies against *L. donovani* 40S ribosomal protein S12 peptides were generated by Abmart (Shanghai) Co. Ltd. However, none of these anti-peptide monoclonal antibodies could recognize the native *L. donovani* 40S ribosomal protein S12 (See discussion). The twelve peptide sequences used to generate the monoclonal antibodies are as follows: NVVVDVAPES, EETVREQEVPA, ECVPAEENVV, VAGETKTLK, QKALEANGVL, FGERTKALDY, ESLEDAVRI, NVEEREKLAQ, TALAKQGNID, VRGLSEVART, QWAGLVRREDEV, EDEEYKVLTV.

**Results**

**Expression and purification of recombinant *Leishmania* proteins in *E. coli***

We hypothesized that abundant *Leishmania* proteins would be more easily detected from clinical samples than low abundance proteins. Therefore, we selected ten soluble and abundant *Leishmania* proteins that were previously identified by proteomic analysis using two-dimension gel electrophoresis and mass spectrometry [25, 26] for production as recombinant proteins in *E. coli* (Table 1). The coding sequences of these abundant *Leishmania* proteins were amplified by PCR from *L. donovani* genomic DNA and cloned into the pET29w expression vector, placing the His-tag at the N-terminus of the expressed recombinant proteins. The His-tagged proteins were purified from *E. coli* lysates on nickel-charged resin columns and the purity was verified by SDS-PAGE (Fig. 1). Eight of the recombinant proteins that met the required yield and purity were used to immunize rabbits to produce polyclonal antisera.

**ELISA analysis of antisera against *L. donovani***

To establish the sensitivity of these rabbit antiserum in detecting *L. donovani* antigens in an ELISA format, microtiter plates were coated with *L. donovani* promastigote lysates (ranging from 10 to 1 million promastigotes per well). Rabbit antisera were diluted 1:2000 and added to the plate followed by the HRP-linked anti-rabbit antibody and the HRP substrate TMB, and the color change at 450 nm absorbance were measured. As shown in Fig. 3a, six of the eight antiserum could detect the corresponding antigen from the *L. donovani* cell lysate in this assay (36,676 and 3582 were the exceptions). Antiserum for 1357 (40S ribosomal protein S12) showed the highest sensitivity with a detection limit of approximately 500 *L. donovani* promastigotes per well.

To determine whether these antiserum could detect *Leishmania* antigen in *L. donovani*-infected macrophages, mouse macrophage B10R cells were infected with *L. donovani*. The lysates of *L. donovani*-infected macrophages were mixed with non-infected macrophage lysates in different ratios and coated on the 96-well plate so that each well contained the same amount of cell lysate from 3000 macrophages (infected plus non-infected) with amastigote numbers ranging from 100 to 6400 per well. As shown in Fig. 3b, the anti-1357 antiserum could detect down to
approximately 200 amastigotes under these conditions and exhibited a *L. donovani* amastigote, dose-dependent increase in the signal. Similarly, signal was detected with human H1299 cell lysates mixed with *L. donovani* infected macrophages down to ~ 200 amastigotes (Fig. 3c). In contrast, although relatively strong signals were detected for the antiserum to *Leishmania* aldolase (36,126), a significant background was also observed for this anti-36,126 antiserum (Fig. 3b and c), likely due to the high sequence identity for the *Leishmania* and human aldolase proteins. Taken together, out of the eight antisera, only the anti-1357 serum to the 40S ribosomal protein S12 gave applicable results and could detect approximately 200 amastigotes per 3000 macrophage lysates per well.

The weak-reacting signals for antigens 36,676, 3582 and 545 could have been due either to poor binding of these *Leishmania* proteins to the plate or poor recognition of these non-denatured or partially denatured proteins. All the antisera except 36,676 and 3582 showed good increases in signal intensity as the number of *L. donovani* promastigotes increased in the lysates, at least up to 100,000 promastigotes (Fig. 3a). However, only 36,126 antiserum produced a signal using 1 million *L. donovani* cells (see below).

It is noteworthy that a *Leishmania* sandwich ELISA developed by Ferrua et al. could detect circular *Leishmania* antigen in sera of *L. infantum* infected visceral leishmaniasis patients with sensitivity like that shown in Fig. 3 [18]. Since the maximum binding capacity of a 96-well ELISA plate well is about 1 μg protein, it is necessary to dilute the *Leishmania* lysate to a concentration of 20 μg/ml (1 μg/50 μl/well) in coating buffer. If the protein concentration is higher than 1 μg/well, then all the binding sites will be saturated and other proteins could compete with the target antigen for binding sites. This could result in loss of
signal, consistent with our observation (Fig. 3a) at lysates from one million L. donovani promastigotes containing about 4 μg protein which could compete with target antigen binding [18].

**Sandwich ELISA for Leishmania 40S ribosomal protein S12 antigen**

Since the binding capacity is limited in the direct ELISA, it could be difficult to detect the antigen if present at low levels or if they fail to adhere to the plastic. In this case, a sandwich (or capture) ELISA may be more sensitive since more of the antigen can be immobilized on the plate.

In this study the rabbit polyclonal antibodies were used as both the capture antibody and the detection antibody in the sandwich ELISA. Total IgG were purified from each of the rabbit antisera, unlabeled purified IgGs (1:2000 dilution) were coated on the ELISA plate as protein-capture antibodies, and one-half of the purified IgG was biotinylated as detection antibody. After blocking and washing, the L. donovani promastigote lysate ranging from 100 to 1 million cells was added into each well of the ELISA plate. The captured Leishmania antigen was
detected with the biotin-labelled IgGs, avidin-HRP, and TMB substrate. As shown in the sandwich ELISA of Fig. 4, only the 40S ribosomal S12 antigen (1357) displayed a dose-dependent signal that became saturated beyond an input of 100,000 promastigotes.

The 40S ribosomal protein S12 (1357) sandwich ELISA was optimized by further dialysis to remove any free biotin conjugates, and various dilutions of capture antibody and detection antibody were tested to improve the signal to noise ratio. After optimization it was possible to detect as little as 1 pg of purified recombinant 40S ribosomal protein S12 (Fig. 5a) and as few as 60 L. donovani parasites either tested alone or mixed with 500,000 human PBMCs from healthy donors (Fig. 5b), which represents PBMCs from about 0.75 ml of blood.

**Analysis of clinical samples with the Leishmania 40S ribosomal protein S12 (1357) sandwich ELISA**

To determine whether this sandwich ELISA could detect the Leishmania 40S ribosomal protein S12 antigen from the clinical samples, PBMCs were isolated from 12 healthy controls, 14 VL patients, 3 post-kala-azar dermal leishmaniasis (PKDL) patients, and 5 likely VL cases before treatment at the Rejandra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, Bihar, India. *Leishmania donovani* (LD) bodies (amastigotes) in the spleen or bone marrow biopsies were positive for the 14 confirmed VL patients, and negative for the 5 likely VL cases that were, however, positive on rK39 Rapid strip test and displayed clinical symptoms of VL including prolonged fever and enlarged spleen (Fig. 6b). All three PKDL cases were confirmed by skin smear microscopy for LD bodies and the 12 healthy controls were from the out-patient department and rK39 negative.

As shown in Fig. 6a, the $A_{450}$ value differences were statistically significant ($P < 0.0001$) between these VL patients (median value, 0.191) and healthy controls (median value, 0.117) or between PKDL patients (median value, 0.185) and healthy controls. It is also noteworthy that while the ELISA values correlate roughly with the score of parasite levels from splenic biopsies (Fig. 6b), this ELISA was also capable of detecting the target 40S ribosomal protein S12 antigen in the PBMC samples of the 5 likely VL cases who were LD-body negative (Fig. 6b). If using the mean of the healthy controls +3SD (standard deviation) as the standard cut-off value (dashed line), 68% (15/22) of the rK39-positive cases (14 VL patients plus 5 likely VL cases) and 3 PKDL patients can be identified as Leishmania 40S ribosomal protein S12 antigen positive. Considering the sensitivity of this ELISA (Fig. 5b), this indicates that these
VL patients could have approximately 15–80 amastigotes per ml of their blood.

**Discussion**

An ELISA was developed to detect *Leishmania* proteins based on the assumption that abundant proteins could be more easily detected than proteins of low abundance in clinical samples. Antibodies raised against the 40S ribosomal protein S12 antigen (1357) outperformed all the other antisera tested and could detect the presence of *L. donovani* in PBMCs from VL patients. Although all the generated rabbit antisera could bind specifically to the corresponding *Leishmania* proteins in denatured form by Western blot analysis, antiserum to the 40S ribosomal S12 antigen was far superior to the other generated antibodies at recognizing their corresponding native *Leishmania* proteins in the ELISA. One explanation for this is that these *E. coli* expressed recombinant proteins were in a different, possibly denatured form that differs from that of the native *Leishmania* proteins. Moreover, we have recently found that antisera raised against some additional abundant *Leishmania* proteins (LdBPK_140910.1; LdBPK_250740.1; LdBPK_363750.1; LdBPK_321910.1 and LdBPK_180690.1) also failed to recognize the native *Leishmania* proteins despite working in Western blot analysis (data not shown). Therefore, future attempts should consider different methods for production and purification of recombinant proteins for generation of antibodies. Different adjuvants could also be considered to produce antibodies that recognize the native *Leishmania* proteins. Another relevant observation from this study is that we synthesized twelve peptide sequences (ten amino acid each) of the 40S ribosomal S12 antigen to generate anti-peptide monoclonal antibodies. However, possibly due to the native protein folding which may hide these epitopes, none of these anti-peptide monoclonal antibodies recognized the native 40S ribosomal protein S12 despite binding to the cognate peptides (See these peptides sequences in Methods).

The 40S ribosomal protein S12 antigen (1357) antiserum could be used to develop a sandwich ELISA that could detect as low as 1 pg purified recombinant 40S ribosomal protein S12 and approximately 60 *Leishmania donovani* parasites. Notably, this ELISA was able to detect the *Leishmania* 40S ribosomal protein S12 antigen in 68% PBMC samples of VL and PKDL patients including the likely VL cases that were LD-body negative in splenic or bone marrow biopsies, but rK39 positive with clinical symptoms. This ELISA also provided a quantitative estimation of the parasitemia for these positive cases. This suggests that this ELISA could be further developed to detect parasitemia for test of cure and relapse and could also be helpful to confirm VL diagnosis of equivocal cases.

While this project was in progress, three *Leishmania* antigen detection tests were reported including a triple *Leishmania* protein detection ELISA (DetectoGen Inc., USA), a *Leishmania* antigen ELISA (Kalon Biologicals Ltd., UK) and a *Leishmania* Antigen Detect™ ELISA (Infectious Disease Research Institute, USA) [20–23]. All these tests detect *Leishmania* antigens with slight differences in sensitivity from urine samples of VL patients, and all could potentially be used to monitor treatment progress. The *Leishmania* antigen ELISA and *Leishmania* Antigen Detect™ ELISA were developed using polyclonal antibodies raised against the whole *Leishmania donovani* cell lysate [23]. The DetectoGen ELISA was developed by raising polyclonal antibodies against three *Leishmania* proteins identified in VL patients’ urine samples [20]. Interestingly, like the 40S ribosomal proteins.
protein S12 (16 kDa), all these three target proteins used in the DetectoGen Inc., capture ELISA (iron superoxide dismutase, 22 kDa; tryparedoxin, 17 kDa; and nuclear transport factor 2, 14 kDa) are also small and abundant Leishmania proteins. The 40S ribosomal protein S12 ELISA being reported in our study has similar sensitivity to the triple protein ELISA (DetectoGen), and is approximately two times more sensitive than the whole cell lysate (WCL) antigen ELISAs. The DetectoGen ELISA has a detection limit ranging from 4 to 100 pg/ml of the target antigens [20–22]. The Detect™ ELISA detection limit is 4 ng/ml, equivalent to about 100 Leishmania parasites per well [23]. We have yet to test whether the 40S ribosomal protein S12 antigen is present in VL patient urine but, if it is, it would be worth determining whether the 40S ribosomal protein S12-IgG complement those in the DetectoGen test, which is also based on anti-recombinant protein antibodies.

Compared with capture ELISAs based on individual antigens, the advantages of WCL capture ELISAs are (1) the ease of preparing the WCL antigens and (2) the greater range of Leishmania proteins (native or denatured) present in various clinical samples that could be recognized by the polyclonal antibodies, potentially resulting in a more sensitive test. In fact, the WCL ELISA may detect predominantly abundant Leishmania proteins that are also present in the urine samples. Based on its genome sequence, Leishmania has approximately 8000 potential proteins, and many of these proteins could significantly increase the likelihood of cross reactions to human proteins, which would increase the background signal. Therefore, it would be useful to compare all the available Leishmania antigen detection ELISAs side-by-side with various clinical samples including urine, blood and PBMCs. With this information, it may be possible to further improve the sensitivity and specificity for Leishmania antigen detection.

**Conclusions**

Progress is described in the development of a sandwich ELISA for detecting Leishmania 40S ribosomal protein S12 in PBMCs of VL and PKDL patients. Though more clinical samples of VL patients and other parasitic diseases such as malaria and trypanosomiasis should be tested to verify its sensitivity and specificity, such a test would be useful for confirming VL diagnosis, relapse cases and monitoring treatment progress. With some refinement and/or in combination with other previously described Leishmania antigen-detecting reagents [20], more sensitive Leishmania antigen detection tests could be developed.

**Abbreviations**

BSA: Bovine serum albumin; ELISA: Enzyme linked immunosorbent assay; IgG: Immunoglobulin G; IPTG: Isopropyl β-D-1-thiogalactopyranoside; PBMC: Peripheral blood mononuclear cell; PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction; PKDL: Post-kala-azar dermal leishmaniasis; rK39 ICT: rK39 immunochromatographic test; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis; VL: Visceral leishmaniasis

**Acknowledgements**

We would like to thank all the VL and PKDL patients and Healthy donors for providing blood samples for this study.

**Funding**

This work was supported by grants from the Bill and Melinda Gates Foundation (OPP49932 and OPP1084251) to SGR and the Canadian Institutes of Health Research to GM. These granting agencies were not involved in data analysis or interpretation.

**Availability of data and materials**

The datasets and materials used and/or analyzed during the current study will be available from the corresponding author on reasonable request.

**Authors’ contributions**

Conceived and designed the experiments: GM, WWZ. Performed the experiments: WWZ, AKG, RM, JW, AP, PL. Analyzed the data: WWZ, AKG and GM. Provided research reagents: MN, PD, SGR and GM. Supervised the research GM, PD, SGR. Wrote the paper: WWZ, RFH and GM. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Boards and Human Ethical Committee of the Rajendra Memorial Research Institute of Medical Sciences (Patna, India) under the project head of “Grand Challenges Canada”. Human PBMCs from whole blood were isolated from healthy and VL/PKDL volunteers after written, informed consent as per standard guidelines.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Microbiology and Immunology, McGill University, 3775 University Street, Montreal, Quebec H3A2B4, Canada. 2Rajendra Memorial Research Institute of Medical Sciences (ICMR), Patna, Bihar, India. 3Infectious Disease Research Institute, Seattle, WA, USA. 4National Reference Center for Parasitology, The Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.

Received: 21 June 2018 Accepted: 27 September 2018

**References**

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
2. Ready PD. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2014;6(6):147–54.
3. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship between leishmaniasis and HIV/AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–59.
4. Belazzougui S. Leishmaniasis in Mediterranean countries. Vet Parasitol. 1992;44:15–9.
5. Quinnell RJ, Courtenay O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology. 2009;136:1915–34.
6. Banu SS, Meyer W, Ahmed BN, Kim R, Lee R. Detection of Leishmania donovani in peripheral blood of asymptomatic individuals in contact with patients with visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2016;110(5):286–93.
7. Singh OP, Hasker E, Borelaet M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016;16(12):e304–9. https://doi.org/10.1016/S1473-3099(16)30140-2.

8. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002;9(5):1–6.

9. Srivastava P, Dayama A, Mehrotra S, Sundar S. Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2011;105:1–6.

10. Sakka H, Gartzonika C, Levidiotou S. Laboratory diagnosis of human visceral leishmaniasis. J Vector Borne Dis. 2016;53(1):8–16.

11. Pattabhi S, Whittle J, Mohamath R, El-Safi S, Moulton GG, Guderian JA, Colombara D, Abdoun AO, Mukhtar M, Ali SS, Boshara SA, Albertini A, Monnerat S, Bessell P, et al. Genetic analysis of Leishmania donovani to cutaneous and visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016;16(12):e304–9. https://doi.org/10.1016/S1473-3099(16)30140-2.

12. Khan MG, Bhaskar KR, Salam MA, Akther T, Pluschke G, Mondal D. Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of Leishmania DNA in buffy coat from visceral leishmaniasis patients. Parasit Vectors. 2012;5(5):280. https://doi.org/10.1186/1756-3305-5-280.

13. Khan MG, Bhaskar KR, Kikuchi M, Salam MA, Akther T, Harque R, et al. Comparison of PCR-based diagnoses for visceral leishmaniasis in Bangladesh. Parasitol Int. 2014;63(2):327–31.

14. Abbasi I, Kisttein OD, Hailu A, Warburg A. Optimization of loop-mediated isothermal amplification (LAMP) assays for the detection of Leishmania DNA in human blood samples. Acta Trop. 2016;162:20–6. https://doi.org/10.1016/j.actatropica.2016.06.009.

15. Verma S, Singh R, Sharma V, Bumb RA, Negi NS, Ramesh V, et al. Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of Leishmania infection. BMC Infect Dis. 2017;17(1):223. https://doi.org/10.1186/s12879-017-2318-8.

16. Mukhtar M, Ali SS, Boshara SA, Albertini A, Monnerat S, Bessell P, et al. Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). PLoS Negl Trop Dis. 2018;12(2):e0006264. https://doi.org/10.1371/journal.pntd.0006264.

17. Adams ER, Schoone G, Vesteeg I, Gomez MA, Duro E, Mori Y, et al. Development and evaluation of a novel LAMP assay for the diagnosis of Cutaneous and Visceral Leishmaniasis. J Clin Microbiol. 2018; pii: doi: https://doi.org/10.1128/JCM.00386-18.

18. Ferrua B, Ril N, Michel G, Marty P. Antigenemia in patients with mediterranean visceral leishmaniasis. J Clin Microbiol. 2009;47(1):3760–2.

19. Salam MA, Khan MG, Bhaskar KR, Afadh MH, Huda MM, Mondal D. Peripheral blood Buffy coat smear: a promising tool for diagnosis of visceral leishmaniasis. J Clin Microbiol. 2012;50(3):837–40.

20. Abeijon C, Kashino SS, Silva FO, Costa DL, Fujiwara RT, Campo-Neto A. Genetic analysis of Leishmania donovani to cutaneous and visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016;16(12):e304–9. https://doi.org/10.1016/S1473-3099(16)30140-2.

21. Abeijon C, Campos-Neto A. Potential non-invasive urine-based antigen (protein) detection assay to diagnose active visceral leishmaniasis. PLoS Negl Trop Dis. 2013;7:e2161.

22. Abeijon C, Singh OP, Chakravarty J, Sundar S, Campos-Neto A. Novel antigen detection assay to monitor therapeutic efficacy of visceral Leishmaniasis. Am J Trop Med Hyg. 2016;95(4):800–2.

23. Vallur AC, Tuttono JV, Mohamath R, Pattabhi S, Hailu A, Abdoun AO, et al. Development and comparative evaluation of two antigen detection tests for visceral leishmaniasis. BMC Infect Dis. 2015;15:384. https://doi.org/10.1186/s12879-015-1125-3.

24. Duro E, Yansouni C, Takélé Y, Mengeha B, Lynen L, Hailu A, et al. Diagnosis of Visceral Leishmaniasis Using Peripheral Blood Microscopy in Ethiopia: A Prospective Phase-III Study of the Diagnostic Performance of Different Concentration Techniques Compared to Tissue Aspiration. Am J Trop Med Hyg. 2016. https://doi.org/10.4269/ajtmh.16-0362.

25. Drummelsmith J, Brochu V, Girard J, Messier N, Ouellette M. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol Cell Proteomics. 2003;2(3):146–55.

26. Bente M, Harder S, Wiesggl M, Heukeshoven J, Gelhaus C, Krause E, et al. Developmentally induced changes of the proteome in the protozoan parasite Leishmania donovani. Proteomics. 2003;3(9):1811–20.

27. McCall Li, Zhang WW, Dejaard K, Atayde VD, Mazur A, Ranasinghe S, et al. Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis. J Proteome Res. 2015;14(2):1033–59. https://doi.org/10.1021/pr5010604.